Sort   by:  
 Page size 
UnknownPhase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.
Not available
S-EPMC9472525 | biostudies-literature
UnknownAtezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Not available
S-EPMC7183720 | biostudies-literature
UnknownA phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
Not available
S-EPMC9463376 | biostudies-literature
UnknownZanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01.
Not available
S-EPMC12635922 | biostudies-literature
UnknownPrediction of Opioid-Induced Respiratory Depression on Inpatient Wards Using Continuous Capnography and Oximetry: An International Prospective, Observational Trial.
Not available
S-EPMC7467153 | biostudies-literature
UnknownEvaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the United States.
Not available
S-EPMC9169655 | biostudies-literature
Sort   by:  
 Page size